Leerink Partnrs dropped their Q2 2025 EPS estimates for Cencora in a report released on Wednesday, February 5th. Leerink Partnrs analyst M. Cherny now forecasts that the company will earn $4.08 per ...

Cencora COR has outperformed the market over the past 5 years by 8.2% on an annualized basis producing an average annual return of 20.8%. Currently, Cencora has a market capitalization of $47.04 ...

Shares of Cencora Inc. COR shed 1.28% to $243.59 Wednesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index SPX falling 0.27% to 6,051.97 and ...

Headquartered in Conshohocken, Pennsylvania, Cencora, Inc. (COR) is a leading pharmaceutical services company dedicated to enhancing global healthcare. With a market cap of $47.7 billion ...

Growth at a reasonable price, or GARP, is an excellent strategy to earn quick investment profits. The GARP approach helps identify stocks priced below the market or any suitable target determined ...

Cencora, Inc. has a twelve month low of $214.77 and a twelve month high of $262.26. The company has a market capitalization of $47.07 billion, a price-to-earnings ratio of 34.64, a PEG ratio of 1. ...

Looking at the universe of stocks we cover at Dividend Channel, on 2/14/25, Cencora Inc (Symbol: COR), Bio-Techne Corp (Symbol: TECH), and Eli Lilly (Symbol: LLY) will all trade ex-dividend for ...

CONSHOHOCKEN, Pa., February 07, 2025--Cencora, Inc. (NYSE: COR) today announced that it has agreed to repurchase shares of its common stock from Walgreens Boots Alliance Holdings LLC in the amount ...

Healthcare and pharmaceuticals have the second largest exposure. Distributors such as McKesson Corp. and Cencora Inc. could face disruption, with the analysts noting government spending is related ...